The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
IGF1R signalling and its inhibition
Abstract
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target. This review outlines the effects of IGF1R activation in tumour cells, and will describe the strategies that are available to block IGF signalling, both as investigational tools and as novel anti-cancer therapeutics. Design of specific IGF1R inhibitors has been problematic due to close homology with the insulin receptor, but recently it has proved possible to design selective IGF1R inhibitors. These compounds and IGF1R antibodies are showing promise in preclinical models of human cancer, and several agents are now in early phase clinical trials. Both classes of agents affect insulin receptor signalling, either by direct kinase inhibition or antibody-induced insulin receptor downregulation. This effect may lead to clinical toxicity, but could be therapeutically beneficial in blocking signalling via variant insulin receptors capable of a mitogenic response to IGF-II. Specificity for IGF1R targeting can be achieved by antisense and siRNA-mediated IGF1R downregulation; these approaches have undoubted utility as research tools, and may in future generate nucleic-acid-based therapeutics. It will be important to use data from preclinical and early clinical trials to establish the molecular correlates of sensitivity to IGF1R blockade, and the optimum means of combining this new approach with standard treatment modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Oncogene · doi:10.1038/sj.onc.1207036 · Cited by 180
RetractedPotent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Liu, J.-P., Baker, J., Perkins, A. S., Robertson, E. J., & Efstratiadis, A. (1993) · Cell · doi:10.1016/s0092-8674(05)80084-4 · Cited by 2,855
Rational siRNA design for RNA interference
Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W. S., & Khvorova, A. (2004) · Nature Biotechnology · doi:10.1038/nbt936 · Cited by 2,094
Ullrich, A., Gray, A., Tam, A. W., Yang-Feng, T., Tsubokawa, M., Collins, C., Henzel, W., Le Bon, T., Kathuria, S., & Chen, E. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04528.x · Cited by 1,844
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & Varmus, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,516
Insulin-like growth factors and neoplasia
Pollak, M. N., Schernhammer, E. S., & Hankinson, S. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1387 · Cited by 1,463
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth
Khandwala, H. M., McCutcheon, I. E., Flyvbjerg, A., & Friend, K. E. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0399 · Cited by 843
Advances in protein kinase B signalling: AKTion on multiple fronts
Brazil, D. P., Yang, Z.-Z., & Hemmings, B. A. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.03.006 · Cited by 830
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
McMenamin, M. E., Soung, P., Perera, S., Kaplan, I. D., Loda, M. F., & Sellers, W. R. (1999) · PubMed · Cited by 640
Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Akiyama, M., Hideshima, T., Chauhan, D., Joseph, M., Libermann, T. A., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00050-9 · Cited by 614
Cadherin Switch in Tumor Progression
HAZAN, R. B., QIAO, R., KEREN, R., BADANO, I., & SUYAMA, K. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1294.016 · Cited by 595
Garcı́a-Echeverrı́a, C., Pearson, M. A., Marti, A., Meyer, T., Mestan, J., Zimmermann, J., Gao, J., Brueggen, J., Capraro, H.-G., Cozens, R., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00051-0 · Cited by 542
Chakravarti, A., Loeffler, J. S., & Dyson, N. J. (2002) · PubMed · Cited by 509
Peruzzi, F., Prisco, M., Dews, M., Salomoni, P., Grassilli, E., Romano, G., Calabretta, B., & Baserga, R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.7203 · Cited by 498
Oligodeoxynucleotides as inhibitors of gene expression: a review.
Stein, C. A., & Cohen, J. S. (1988) · PubMed · Cited by 420
The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo.
Resnicoff, M., Abraham, D., Yutanawiboonchai, W., Rotman, H. L., Kajstura, J., Rubin, R., Zoltick, P. W., & Baserga, R. (1995) · PubMed · Cited by 385
Hellawell, G. O., Turner, G. D. H., Davies, D. R., Poulsom, R., BREWSTER, S. F., & Macaulay, V. M. (2002) · PubMed · Cited by 372
Self-citationThe Role of the IGF System in Cancer: From Basic to Clinical Studies and Clinical Applications
Moschos, S. J., & Mantzoros, C. S. (2002) · Oncology · doi:10.1159/000066230 · Cited by 371
Noise amidst the silence: off-target effects of siRNAs?
Jackson, A. L., & Linsley, P. S. (2004) · Trends in Genetics · doi:10.1016/j.tig.2004.08.006 · Cited by 368
Cohen, B. D., Baker, D. A., Soderstrom, C., Tkalcevic, G., Rossi, A. M., Miller, P. E., Tengowski, M. W., Wang, F., Gualberto, A., Beebe, J. S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1070 · Cited by 365
Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth
Girnita, A., Girnita, L., Prete, F. D., Bartolazzi, A., Larsson, O., & Axelson, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2522 · Cited by 363
Structure and autoregulation of the insulin-like growth factor 1 receptor kinase.
Favelyukis, S., Till, J. H., Hubbard, S. R., & Miller, W. T. (2001) · Nature Structural Biology · doi:10.1038/nsb721 · Cited by 336
Arteaga, C. L., Kitten, L. J., Coronado, E. B., Jacobs, S., Kull, F. C., Allred, D. C., & Osborne, C. K. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114315 · Cited by 328
Worthylake, R., Opresko, L. K., & Wiley, H. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8865 · Cited by 325
Scotlandi, K., Manara, M. C., Nicoletti, G., Lollini, P.-L., Lukas, S., Benini, S., Croci, S., Perdichizzi, S., Zambelli, D., Serra, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3192 · Cited by 299
Kretschmer-Kazemi Far, R. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg649 · Cited by 291
Playford, M. P., Bicknell, D., Bodmer, W. F., & Macaulay, V. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.210394297 · Cited by 280
Self-citationDunn, S. E., Ehrlich, M., Sharp, N., Krzysztof Reiss, F., Solomon, G., Hawkins, R., Baserga, R., & Barrett, J. C. (1998) · PubMed · Cited by 279
Lopez, T., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00055-7 · Cited by 268
Pandini, G., Vigneri, R., Costantino, A., Frasca, F., Ippolito, A. M., Fujita‐Yamaguchi, Y., Siddle, K., Goldfine, I. D., & Belfiore, A. (1999) · PubMed · Cited by 255
Filleur, S., Courtin, A., Ait‐Si‐Ali, S., Guglielmi, J., Arnold, C., Harel‐Bellan, A., Clézardin, P., & Cabon, F. (2003) · PubMed · Cited by 253
Alvarez, J. V., Greulich, H., Sellers, W. R., Meyerson, M., & Frank, D. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3757 · Cited by 240
Bohula, E. A., Salisbury, A. J., Sohail, M., Playford, M. P., Riedemann, J., Southern, E. M., & Macaulay, V. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300714200 · Cited by 237
Self-citationAndrews, D. W., Resnicoff, M., Flanders, A. E., Kenyon, L., Curtis, M., Merli, G., Baserga, R., Iliakis, G., & Aiken, R. D. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2189 · Cited by 222
Dunn, S. E., Hardman, R. A., Kari, F. W., & Barrett, J. C. (1997) · PubMed · Cited by 204
Sachdev, D., Li, S. L., Hartell, J. S., Fujita‐Yamaguchi, Y., Miller, J. S., & Yee, D. (2003) · PubMed · Cited by 190
Haluska, P., Carboni, J. M., Loegering, D. A., Lee, F. Y., Wittman, M., Saulnier, M. G., Frennesson, D. B., Kalli, K. R., Conover, C. A., Attar, R. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1107 · Cited by 179
Wang, Y., Hailey, J., Williams, D., Wang, Y., Lipari, P., Malkowski, M., Wang, X., Xie, L., Li, G., Saha, D., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0048 · Cited by 171
Wu, J. D., Odman, A., Higgins, L. M., Haugk, K., Vessella, R., Ludwig, D. L., & Plymate, S. R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1586 · Cited by 167
Sciacca, L., Mineo, R., Pandini, G., Murabito, A., Vigneri, R., & Belfiore, A. (2002) · Oncogene · doi:10.1038/sj.onc.1206058 · Cited by 162
Stromberg, T. (2006) · Blood · doi:10.1182/blood-2005-01-0306 · Cited by 158
Lahm, H., Amstad, P., Wyniger, J., Yilmaz, A., Fischer, J. R., Schreyer, M., & Givel, J. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910580325 · Cited by 143
Kokubo, Y., Gemma, A., Noro, R., Seike, M., Kataoka, K., Matsuda, K., Okano, T., Minegishi, Y., Yoshimura, A., Shibuya, M., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602559 · Cited by 137
Trojanek, J., Ho, T., Valle, L. D., Nowicki, M. O., Wang, J. Y., Lassak, A., Peruzzi, F., Khalili, K., Skórski, T., & Reiss, K. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7510-7524.2003 · Cited by 134
Macaulay, V. M., Salisbury, A. J., Bohula, E. A., Playford, M. P., Smorodinsky, N. I., & Shiloh, Y. (2001) · Oncogene · doi:10.1038/sj.onc.1204565 · Cited by 128
Self-citationPlosker, G. L., & Keam, S. J. (2006) · Drugs · doi:10.2165/00003495-200666040-00005 · Cited by 127
Phosphorothioate Oligodeoxynucleotides: Antisense or Anti-Protein?
Krieg, A. Μ., & Stein, C. (1995) · Antisense Research and Development · doi:10.1089/ard.1995.5.241 · Cited by 127
Valentinis, B., Romano, G., Peruzzi, F., Morrione, A., di Prisco, M., Soddu, S., Cristofanelli, B., Sacchi, A., & Baserga, R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.18.12423 · Cited by 124
Development of New Insulin-like Growth Factor-1 Receptor Kinase Inhibitors Using Catechol Mimics
Blum, G., Gazit, A., & Levitzki, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305490200 · Cited by 120
Girnita, A., All‐Ericsson, C., Economou, M. A., Astr√∂m, K., Axelson, M., Seregard, S., Larsson, O., & Girnita, L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1106 · Cited by 120
Treins, C., Giorgetti‐Peraldi, S., Murdaca, J., Monthouel, M.-N., & OBBERGHEN, E. V. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0239 · Cited by 120
Sachdev, D., Singh, R., Fujita‐Yamaguchi, Y., & Yee, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3126 · Cited by 119
YOUNGREN, J. F., Gable, K., Peñaranda, C., Maddux, B. A., Zavodovskaya, M., Lobo, M., Campbell, M. J., Kerner, J., & Goldfine, I. D. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-6939-z · Cited by 117
Rochester, M. A., Riedemann, J., Hellawell, G. O., BREWSTER, S. F., & Macaulay, V. M. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700775 · Cited by 115
Self-citationTargeting insulin-like growth factor pathways
Yee, D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602963 · Cited by 114
Selecting optimal antisense reagents
Sohail, M., & Southern, E. M. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00081-8 · Cited by 104
Valentinis, B., Navarro, M., Zanocco‐Marani, T., Edmonds, P. R., McCormick, J., Morrione, A., Sacchi, A., Romano, G., Reiss, K., & Baserga, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002271200 · Cited by 99
Adams, T. E., McKern, N. M., & Ward, C. W. (2004) · Growth Factors · doi:10.1080/08977190410001700998 · Cited by 97
Dritschilo, A., Huang, C. H., Rudin, C. M., Marshall, J. L., Collins, B., Dul, J. L., Zhang, C., Kumar, D., Gokhale, P. C., Ahmad, A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1260 · Cited by 91
Zhang, D., Samani, A. A., & Brodt, P. (2003) · Hormone and Metabolic Research · doi:10.1055/s-2004-814143 · Cited by 86
O’Gorman, D. B., Weiss, J., Hettiaratchi, A., Firth, S. M., & Scott, C. D. (2002) · Endocrinology · doi:10.1210/en.2002-220548 · Cited by 82
Shen, M., Hsu, Y.-M., Hsu, K., Chen, Y., Tang, M., & Chou, C.-Y. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi336 · Cited by 82
IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation
Krzysztof Reiss, F., Wang, J., Romano, G., Furnari, F. B., Cavenee, W. K., Morrione, A., Tu, X., & Baserga, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203587 · Cited by 82
Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment
Bohula, E. A., Playford, M. P., & Macaulay, V. M. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200310000-00001 · Cited by 80
Self-citationGable, K., Maddux, B. A., Peñaranda, C., Zavodovskaya, M., Campbell, M. J., Lobo, M., Robinson, L., Schow, S. R., Kerner, J. A., Goldfine, I. D., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0397 · Cited by 68
Yeh, A. H., Bohula, E. A., & Macaulay, V. M. (2006) · Oncogene · doi:10.1038/sj.onc.1209674 · Cited by 66
Self-citationThe IGFI receptor gene: A molecular target for disrupted transcription factors
Werner, H., & Roberts, C. T. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10157 · Cited by 63
Insulin and Hybrid Insulin/IGF Receptors Are Major Regulators of Breast Cancer Cells
Frasca, F., Pandini, G., Vigneri, R., & Goldfine, I. D. (2003) · Breast Disease · doi:10.3233/bd-2003-17108 · Cited by 62
Harper, J., Burns, J. L., Foulstone, E. J., Pignatelli, M., Zaina, S., & Hassan, A. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2036 · Cited by 60
Transformation by the simian virus 40 T antigen is regulated by IGF-I receptor and IRS-1 signaling
DeAngelis, T., Chen, J., Wu, A., di Prisco, M., & Baserga, R. (2005) · Oncogene · doi:10.1038/sj.onc.1209013 · Cited by 56
Vasilcanu, D., Weng, W.-H., Girnita, A., Lui, W., Vasilcanu, R., Axelson, M., Larsson, O. S., Larsson, C., & Girnita, L. (2005) · Oncogene · doi:10.1038/sj.onc.1209339 · Cited by 48
IGF-1: Old Growth Factor Shines as New Drug Target
Garber, K. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/97.11.790 · Cited by 45
Lee, J. S., Weiss, J., Martin, J. L., & Scott, C. D. (2003) · International Journal of Cancer · doi:10.1002/ijc.11453 · Cited by 43
Furlanetto, R. W., Harwell, S. E., & Rb, B. (1993) · PubMed · Cited by 41
Delayed Onset of Igf2-Induced Mammary Tumors in Igf2r Transgenic Mice
Wise, T. L., & Pravtcheva, D. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3107 · Cited by 37
Bell, I. M., Stirdivant, S. M., Ahern, J. D., Culberson, J. C., Darke, P. L., Dinsmore, C. J., Drakas, R. A., Gallicchio, S. N., Graham, S. L., Heimbrook, D. C., et al. (2005) · Biochemistry · doi:10.1021/bi0500628 · Cited by 32
Ward, C. W., & Garrett, T. (2004) · PubMed · Cited by 28
Wang, H., Wang, S., Nan, L., Yu, D. S., Agrawal, S., & Zhang, R. (2002) · International Journal of Oncology · doi:10.3892/ijo.20.4.745 · Cited by 24
Fogarty, R. D., McKean, S. C., White, P. J., Atley, L. M., Werther, G. A., & Wraight, C. J. (2002) · Antisense and Nucleic Acid Drug Development · doi:10.1089/108729002321082447 · Cited by 5
Cited by
Anti-inflammatory mechanisms of bioactive milk proteins in the intestine of newborns
Chatterton, D. E. W., Nguyen, D. N., Bering, S. B., & Sangild, P. T. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.04.028 · Cited by 402
Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer
Clemmons, D. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2359 · Cited by 340
Heikkilä, K., Harris, R., Lowe, G., Rumley, A., Yarnell, J., Gallacher, J., Ben-Shlomo, Y., Ebrahim, S., & Lawlor, D. A. (2009) · Cancer Causes & Control · doi:10.1007/s10552-008-9212-z · Cited by 290
Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies
Brahmkhatri, V. P., Prasanna, C., & Atreya, H. S. (2015) · BioMed Research International · doi:10.1155/2015/538019 · Cited by 279
Melnik, B. C., & Schmitz, G. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2009.00924.x · Cited by 266
Metadata
- Authors
- Riedemann, J., & Macaulay, V. M.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2006-12
- Volume
- 13
- Issue
- Supplement_1
- Pages
- S33-S43
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2146736665
- Cited by
- 301
- References
- 86
- FWCI
- 9.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.